Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive

Next Previous
X
Search
Trial Profile

A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Disitamab vedotin (Primary)
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors RemeGen

    • Most Recent Events

    • 08 Jun 2021 Results of a pooled analysis of data from two phase I studies (C001 CANCER (NCT02881138) and C003 CANCER (NCT03052634)) assessing the for the efficacy and safety in HER2-positive or HER2-low expressing subgroups presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 28 Jul 2020 Status changed from recruiting to completed.
    • 27 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top